共 14 条
[1]
The hirulog and early reperfusion or occlusion(HERO)-2trial investigators.Thrombin-specific anticoagu-lation with bivalirudin versus heparin in patients receiving fibrinolytic therapy for acute myocardial infarction:the HERO-2randomised trial. White H. The Lancet . 2001
[2]
Effects of ximela-gatran,an oral direct thrombin inhibitor,r-hirudin and enoxaparin on thrombin generation and platelet activation in healthy male subjects. Sarich TC,Wolzt M,Eriksson UG,et al. Journal of the American College of Cardiology . 2003
[3]
Ximelagatran vs Warfarin for stroke preven-tion in patients with nonvalvular atrial fibrillation:a ran-domized trial. SPORTIF Executive Steering Committee for the SPORTIF V Investigators. The Journal of The American Medical Association . 2005
[4]
Long-term efficacy of bivalirudin and provisional glycoproteinⅡb/Ⅲa blockade vs heparin and planned glycoproteinⅡb/Ⅲa blockade during percutaneous coronary revascularization:REPLACE-2randomized trial. Lincoff AM,Kleiman NS,Kereiakes DJ,et al. The Journal of The American Medical Association . 2004
[5]
Direct thrombin inhibitors in acute coronary syndromes. Weitz JI,Buller HR. Circulation . 2002
[6]
Treatment with bi-valirudin(Hirulog)as compared with heparin during coro-nary angioplasty for unstable or post infarction angina.Hir-ulog Angioplasty Study Investigators. Bittl JA,Strony J,Brinker JA,et al. The New England Journal of Medicine . 1995
[7]
Bivalirudin and provisional glycoproteinⅡb/Ⅲa blockade compared with heparin and planned glycoproteinⅡb/Ⅲa blockade during percutaneous coronary Intervention:REPLACE-2random-ized trial. Lincoff AM,Bittl JA,Harrington RA,et al. The Journal of The American Medical Association . 2003
[8]
Bivalirudin versus heparin during coronary angioplasty for unstable or postinfarction angina:Final report reanalysis of the bivalirudin angioplasty study. Bittl JA,Chaitman BR,Feit F,et al. American Heart Journal . 2001
[9]
Multicenter,dose-ranging study of efegatran sulfate versus heparin with thrombolysis for acute myocardial infarction:The promotion of reperfusion in myocardial infarction evolution(PRIME)trial. The PRIME Investigators. American Heart Journal . 2002
[10]
Bivalirudin with planned or provisional abciximab versus low-dose heparin and abciximab during percutaneous coronary revascularization:Results of the comparison of abciximab complications with hirulog for ischemic events trial(CACHET). Lincoff AM,Kleiman NS,Kottke-Marchant K,et al. American Heart Journal . 2002